- Home
- PRG vs MIRM Comparison
PRG vs MIRM Comparison
Compare PRG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | MIRM |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 7.2B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRG | MIRM |
|---|---|---|
| Price | $35.74 | $98.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $50.00 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 451.3K | 420.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,409,223,000.00 | $19,138,000.00 |
| Revenue This Year | $23.77 | $26.22 |
| Revenue Next Year | $7.91 | $22.04 |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.80 | $63.23 |
| 52 Week High | $47.73 | $130.00 |
Technical Indicators
Market Signals| Indicator | PRG | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 33.29 | 50.89 |
| Support Level | $32.30 | $88.08 |
| Resistance Level | $36.85 | $105.20 |
| Average True Range (ATR) | 1.08 | 3.49 |
| MACD | -0.11 | 0.35 |
| Stochastic Oscillator | 7.11 | 70.89 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.